Saxenda for Binge Eating Disorder: What the Evidence Actually Shows

What Is Binge Eating Disorder and Why Is It Hard to Treat?

Binge eating disorder is the most common eating disorder in the United States, affecting roughly 2.8% of adults over their lifetime according to data from the National Comorbidity Survey Replication published in Biological Psychiatry. BED is defined by recurrent episodes of eating large quantities of food in a discrete period, paired with a sense of loss of control and marked distress, without the compensatory behaviors seen in bulimia nervosa [1].

Treatment options remain limited. The FDA has approved only one medication specifically for BED: lisdexamfetamine dimesylate (Vyvanse), based on two Phase III trials that showed significant reductions in binge days per week [2]. Cognitive behavioral therapy (CBT) is considered first-line by the American Psychological Association, but access is often constrained by cost and availability [3]. Selective serotonin reuptake inhibitors and topiramate are used off-label, though evidence for sustained binge reduction is mixed according to a Cochrane systematic review [4]. That leaves clinicians searching for additional pharmacologic tools, and GLP-1 receptor agonists have entered the conversation.

Why Clinicians Are Looking at Saxenda for BED

The rationale is biological, not speculative. GLP-1 receptors are expressed throughout the central nervous system, including the hypothalamus, nucleus tractus solitarius, and mesolimbic reward circuits. Activation of these receptors by liraglutide reduces appetite and caloric intake through both homeostatic and hedonic pathways, as described in a review published in Diabetes, Obesity and Metabolism [5]. Animal models have demonstrated that GLP-1 receptor agonists decrease binge-like eating behavior in rodents exposed to intermittent high-fat diets, a finding reported in Neuropsychopharmacology [6].

This distinction matters for BED specifically. Unlike simple overeating, binge episodes involve a reward-driven compulsive component. Research published in the American Journal of Psychiatry has identified altered dopaminergic signaling in patients with BED that overlaps with patterns seen in substance use disorders [7]. GLP-1 receptor agonists modulate dopamine release in the ventral tegmental area, suggesting a mechanism through which drugs like liraglutide could target the compulsive dimension of binge eating rather than appetite alone [5,6].

Saxenda (liraglutide 3 mg) received FDA approval in December 2014 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [8]. It holds no FDA indication for any eating disorder. Any use in BED is off-label.

The Key Clinical Trial: Robert et al. (2024)

The most relevant piece of human evidence is a double-blind, randomized, placebo-controlled trial published in the Journal of Clinical Psychiatry [9]. This study enrolled 44 adults who met DSM-5 criteria for BED. Participants were randomized to receive liraglutide (titrated to 3 mg/day) or matching placebo for 12 weeks.

Results showed that the liraglutide group experienced a statistically significant reduction in binge eating episodes per week compared to placebo. The liraglutide group also showed greater improvement on the Binge Eating Scale (BES), a validated self-report measure of binge severity. Secondary outcomes included reductions in body weight and improvements in scores on the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating (Y-BOCS-BE), indicating reduced preoccupation with food and eating rituals [9].

The trial had clear limitations. Forty-four participants is a small sample. The 12-week duration cannot speak to durability of response or what happens after discontinuation. Dropout was notable in the liraglutide arm, primarily from gastrointestinal side effects. Still, this remains the only published RCT examining liraglutide specifically for BED, and the signal was consistent across multiple outcome measures [9].

Supporting Evidence: Case Reports and Open-Label Data

Beyond the Robert et al. RCT, several smaller studies contribute to the picture. An open-label pilot study by Da Porto and colleagues, published in Eating and Weight Disorders, examined liraglutide 1.8 mg (the diabetes dose, lower than the weight-management dose) in 15 patients with type 2 diabetes and comorbid BED [10]. Over 12 weeks, binge frequency dropped significantly and Binge Eating Scale scores improved. The overlap of metabolic disease and BED in this cohort makes it difficult to isolate the eating-disorder effect from improved glycemic control and weight loss, but the binge-specific outcomes were encouraging [10].

A retrospective chart review presented at the 2023 Obesity Society annual meeting examined 28 patients with BED prescribed liraglutide 3 mg and tracked for 24 weeks. Self-reported binge episodes declined by approximately 60% from baseline. These data have not been published in a peer-reviewed journal, which limits their weight in evidence hierarchies [11].

Case reports published in Obesity Research & Clinical Practice describe individual patients with treatment-resistant BED who experienced marked reduction in binge frequency after starting liraglutide, with some maintaining response for over six months [12]. Case reports sit at the lowest tier of evidence, but they document a pattern: the effect on binge episodes appears at least partially independent of weight loss.

How Does Liraglutide Compare to FDA-Approved BED Treatment?

Lisdexamfetamine (Vyvanse) remains the only medication with an FDA-approved indication for moderate-to-severe BED. In the two Phase III registration trials published in JAMA Psychiatry, lisdexamfetamine 50 mg and 70 mg daily produced significantly greater reductions in binge days per week versus placebo, with effect sizes in the moderate-to-large range across both studies (N=724 combined) [2]. The evidence base for lisdexamfetamine is substantially larger and more mature than what exists for liraglutide.

Direct head-to-head comparison data do not exist. A comparison on several dimensions is useful, though:

Mechanism. Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant. It reduces binge eating likely through enhanced dopaminergic and noradrenergic signaling in prefrontal-striatal circuits, as described by the Endocrine Society clinical practice resources [13]. Liraglutide works through GLP-1 receptor activation, modulating appetite and reward signaling without stimulant properties [5].

Side-effect profile. Lisdexamfetamine carries a Schedule II controlled-substance classification because of its abuse potential. Common adverse events include insomnia, dry mouth, and increased heart rate [2]. Liraglutide's common side effects are gastrointestinal: nausea (affecting up to 39% of patients in the SCALE Obesity and Prediabetes trial), vomiting, diarrhea, and constipation, as documented in the FDA prescribing information [8]. It carries a boxed warning for thyroid C-cell tumors based on rodent data, though the clinical relevance in humans remains uncertain according to a review in The Lancet Diabetes & Endocrinology [14].

Weight effects. Lisdexamfetamine produces modest weight loss. Liraglutide 3 mg produced a mean weight loss of 8.0% versus 2.6% with placebo at 56 weeks in the SCALE trial (N=3,731), published in the New England Journal of Medicine [15]. For patients with BED and comorbid obesity, the dual effect on binge behavior and weight may be clinically meaningful.

What About Semaglutide and Other GLP-1 Agonists for BED?

Semaglutide (Wegovy 2.4 mg weekly, Ozempic 0.5-2 mg weekly) has generated interest for BED as well, though published BED-specific data are even sparser than for liraglutide. A secondary analysis of the STEP-1 trial (N=1,961, published in the New England Journal of Medicine) did not specifically assess binge eating as an outcome, but participants on semaglutide 2.4 mg reported reduced appetite and food cravings, which overlaps with BED-relevant constructs [16].

An ongoing NIH-registered clinical trial (NCT05217082) is examining semaglutide specifically for BED, with results expected in 2026. Until those data emerge, liraglutide has the stronger (if still limited) evidence base for this off-label use, and clinicians should not assume class-wide equivalence without supporting trial data. The National Institute of Diabetes and Digestive and Kidney Diseases provides general information on BED management but does not currently list GLP-1 agonists among recommended treatments [17].

Dosing, Titration, and Practical Considerations

If a clinician and patient decide to trial liraglutide for BED off-label, the standard Saxenda titration schedule applies: 0.6 mg daily for week 1, increasing by 0.6 mg each week until reaching the target of 3 mg daily by week 5 [8]. This gradual escalation reduces gastrointestinal side effects, which are the leading cause of discontinuation.

Patients should be counseled on several points. The prescription is off-label, meaning the FDA has not evaluated liraglutide for BED. Insurance coverage may be challenging. Nausea typically peaks during weeks 2 through 4 and improves with continued use in most patients [8]. Monitoring should include assessment of binge frequency (a food/episode diary is standard in BED research), mood, and weight. Concurrent psychotherapy, particularly CBT, is recommended by the APA guideline on eating disorders regardless of pharmacotherapy choice [3].

Contraindications per the FDA label include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and known hypersensitivity to liraglutide. Saxenda should not be combined with other GLP-1 receptor agonists, including insulin products containing liraglutide, as noted in the FDA safety communication and prescribing information [8].

What Guidelines Say (and Don't Say)

The 2023 American Psychiatric Association Practice Guideline for eating disorders recommends lisdexamfetamine for moderate-to-severe BED when pharmacotherapy is indicated, alongside CBT [3]. It does not mention liraglutide or GLP-1 receptor agonists. The Endocrine Society clinical practice guidelines on obesity pharmacotherapy acknowledge liraglutide 3 mg for weight management but do not address BED as a treatment target [13].

The American Association of Clinical Endocrinology (AACE) obesity management guidelines, updated in 2023, include liraglutide in their pharmacotherapy algorithm for obesity but similarly do not discuss eating-disorder indications [18]. No major U.S. or European guideline body currently recommends GLP-1 receptor agonists for BED at any level of evidence.

This absence does not mean the approach is wrong. It means the evidence has not yet reached the threshold for guideline inclusion. A single small RCT and a handful of pilot studies are insufficient by GRADE methodology standards for a recommendation, even a conditional one.

Risks, Limitations, and Unanswered Questions

The safety profile of liraglutide at 3 mg is well-characterized from weight-management trials. In the SCALE Obesity and Prediabetes trial, 9.8% of liraglutide-treated patients discontinued due to adverse events, primarily gastrointestinal, compared to 4.3% on placebo [15]. Acute pancreatitis occurred in 0.4% of liraglutide patients versus 0.1% on placebo. Gallbladder-related events were also more frequent in the active-treatment group, consistent with the effects of rapid weight loss [15].

BED-specific risks are less well-studied. One concern is rebound binge eating after discontinuation. Weight regain after stopping GLP-1 agonists is well-documented, as shown in the STEP-1 extension study published in Diabetes, Obesity and Metabolism [19]. Whether a similar rebound occurs with binge eating behavior is unknown and represents a critical gap.

Patients with BED and a history of anorexia nervosa or purging behaviors require careful evaluation. The appetite-suppressive effects of GLP-1 agonists could theoretically reinforce restrictive patterns in vulnerable individuals, though this has not been systematically studied. A commentary in the International Journal of Eating Disorders raised this concern explicitly and called for inclusion of eating-disorder screening in GLP-1 agonist prescribing protocols [20].

The Bottom Line for Clinicians and Patients

Liraglutide 3 mg (Saxenda) is not an evidence-based treatment for binge eating disorder. It is an FDA-approved weight-management drug with preliminary but biologically plausible signals suggesting benefit for binge frequency reduction. The Robert et al. RCT (N=44, 12 weeks) is the best available human evidence and showed positive results across binge frequency, binge severity, and obsessive-compulsive eating measures [9].

For patients with BED and comorbid obesity who have not responded to or cannot tolerate lisdexamfetamine, a supervised off-label trial of liraglutide 3 mg is a reasonable clinical discussion, paired with structured psychotherapy and informed consent about the off-label status. Clinicians should document binge frequency at baseline and at 8 and 12 weeks using a validated instrument such as the Binge Eating Scale, discontinuing if no meaningful reduction in episodes is observed.